MAP2K7 and melanoma: A correlation has been shown between NRAS mutation and loss of CDKN2A expression through promoter hypermethylation [71], potentially explaining the loss of p16INK4A in BRAF/MEK inhibitor-resistant melanoma with NRAS mutations.